ClinicalTrials.gg
RecruitingNCT07282015HS-RISEUpdated Jun 23, 2026

Real-world Secukinumab Outcomes in Canadian HS Patients

An observational study in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Recruiting at 15 sites in Canada. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
142
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Planned enrollment
5th of 10
142 · median 125
Started
2025
with 6 others
Observational
10 of 21
6 open now
Primary completion
2028-02
later than 10 of 13 live
Registered
16th of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is one of 7 that started in 2025, is one of 10 observational ones, reaches primary completion later than 10 of the 13 other live ones, and was the 16th registered.

Hidradenitis Suppurativa

286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis Suppurativa
  • NIS
  • secukinumab
  • Phase IV
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Canadian patients diagnosed with moderate-to-severe HS and treated with secukinumab as per routine clinical practice

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must give written, signed, and dated before any information is collected and any study-related activity is performed.
  2. Adult patients at the time of informed consent signature.
  3. Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist.
  4. Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit.
  5. Patients who can understand written and spoken Canadian English or French.

Exclusion criteria

Exclusion Criteria:

  1. Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation.
  2. Patients who have any to treatment with secukinumab, as defined in the Canadian PM.
  3. Patients who have had any prior exposure to secukinumab (i.e., >7 days prior to the baseline visit).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
142 participants (estimated)
Patient registry
No

Groups and cohorts

  • Secukinumab

    Patients with moderate-to-severe HS who are prescribed secukinumab in Canadian routine clinical practice

06

What researchers measure

Primary outcomes

  1. Proportion of patients who experience a change in disease severity classification

    Proportion of patients who experience a change in disease severity classification from baseline to 12 months, as determined by the International HS Severity Score System (IHS4). Determining IHS4 score requires counting nodules, abscesses and draining tunnels/sinus tracts. A score of 3 or less signifies mild HS, a score of 4 to 10 signifies moderate HS, and a score of 11 or higher signifies severe HS.

    Time frame: Baseline, month 12

Secondary outcomes

  1. Proportion of patients overall who experience a change in disease severity classification

    Proportion of patients overall who experience a change in disease severity classification as determined by IHS4 from baseline at Months 3 and 6; additional subgroups analyses by ethnicity/race. Determining IHS4 score requires counting nodules, abscesses and draining tunnels/sinus tracts. A score of 3 or less signifies mild HS, a score of 4 to 10 signifies moderate HS, and a score of 11 or higher signifies severe HS.

    Time frame: Baseline, Month 3, Month 6

  2. Proportion of patients achieving a 55% reduction in International HS Severity Score System (IHS4-55)

    Proportion of patients achieving IHS4-55 at Months 3, 6, and 12; additional subgroups analyses by ethnicity/race. IHS4-55 is defined as at least a 55% reduction in their IHS4 from baseline.

    Time frame: Baseline, Month 3, Month 6, Month 12

  3. Proportion of patients experiencing HS Clinical Response 50 (HiSCRO50)

    Proportion of patients achieving a 50% reduction from baseline in HS Clinical Response Score (HiSCR50) at Months 3, 6, and 12; additional subgroups analyses by ethnicity/race. HiSCR50 is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscesses or draining fistulae count.

    Time frame: Baseline, Month 3, Month 6, Month 12

  4. Mean reduction in abscess and inflammatory nodule count

    Mean reduction in abscess and inflammatory nodule count from baseline at Months 3, 6, and 12; additional subgroups analyses by ethnicity/race

    Time frame: Baseline, Month 3, Month 6, Month 12

  5. Descriptive summaries of demographic and clinical variables

    Descriptive summaries demographic and clinical variables

    Time frame: Baseline

  6. Proportion of patients receiving secukinumab up-titration from every 4 weeks (Q4W) to every 2 weeks (Q2W)

    Proportion of patients receiving secukinumab up-titration from Q4W to Q2W at Months 3, 6, and 12; Subgroup analysis by ethnicity/race as well as time to biologic treatment initiation

    Time frame: Month 3, Month 6, Month 12

  7. Proportion of patients receiving secukinumab down-titration from every 2 weeks (Q2W) to every 4 weeks (Q4W)

    Proportion of patients receiving secukinumab down-titration from Q2W to Q4W at Months 3, 6, and 12; Subgroup analysis by ethnicity/race as well as time to biologic treatment initiation

    Time frame: Month 3, Month 6, Month 12

  8. Time to secukinumab up- and down-titration

    Time to secukinumab up- and down-titration

    Time frame: Month 3, Month 6, Month 12

  9. Proportion of patients experiencing adverse events post-secukinumab initiation

    Proportion of patients experiencing adverse events post-secukinumab initiation

    Time frame: Up to 12 Months

  10. Proportion of patients experiencing serious adverse events post-secukinumab initiation

    Proportion of patients experiencing serious adverse events post-secukinumab initiation

    Time frame: Up to 12 Months

  11. Type of adverse events and serious adverse events experienced by patients post-secukinumab initiation

    Type of adverse events and serious adverse events experienced by patients post-secukinumab initiation

    Time frame: Up to 12 Months

  12. Proportion of patients who discontinued secukinumab due to adverse events

    Proportion of patients who discontinued secukinumab due to adverse events

    Time frame: Up to 12 Months

  13. Proportion of patients receiving additional HS-related therapies

    Proportion of patients receiving additional HS-related therapies at Months 3, 6, and 12; additional subgroup analysis by dosing, ethnicity/race and time to biologic initiation

    Time frame: Month 3, Month 6, Month 12

  14. Proportion of patients requiring unplanned surgeries

    Proportion of patients requiring unplanned surgeries at Month 3, 6, and 12; additional subgroup analysis by dosing, ethnicity/race and time to biologic initiation

    Time frame: Month 3, Month 6, Month 12

  15. Proportion of patients discontinuing secukinumab treatment

    Proportion of patients discontinuing secukinumab treatment at Months 3, 6, and 12; additional sugbroup analyses also done by ethnicity/race

    Time frame: Month 3, Month 6, Month 12

  16. Reason(s) for secukinumab discontinuation

    Reason(s) for secukinumab discontinuation; additional subgroup analyses by ethnicity/race

    Time frame: Up to 12 Months

  17. Percentage of no-show appointments which were scheduled as per standard of care

    Percentage of no-show appointments which were scheduled as per standard of care with participating dermatologist (including injections) and the corresponding reason(s); additional subgroup analyses by ethnicity/race

    Time frame: Up to 12 Months

07

Study locations

15 of 15 sites recruiting
  • Novartis Investigative Site
    Calgary, Alberta T2J 7E1, Canada
    Recruiting
  • Novartis Investigative Site
    Calgary, Alberta T3E 0B2, Canada
    Recruiting
  • Novartis Investigative Site
    Winnipeg, Manitoba R3M 3Z4, Canada
    Recruiting
  • Novartis Investigative Site
    Fredericton, New Brunswick E3B 1G9, Canada
    Recruiting
  • Novartis Investigative Site
    St. John's, Newfoundland and Labrador A1E 1V4, Canada
    Recruiting
  • Novartis Investigative Site
    Cobourg, Ontario K9A 4J9, Canada
    Recruiting
  • Novartis Investigative Site
    Hamilton, Ontario L8P4B4, Canada
    Recruiting
  • Novartis Investigative Site
    London, Ontario N6H 5L5, Canada
    Recruiting
  • Novartis Investigative Site
    Markham, Ontario L3P 1X3, Canada
    Recruiting
  • Novartis Investigative Site
    Mississauga, Ontario L4W 0C2, Canada
    Recruiting
  • Novartis Investigative Site
    Richmond Hill, Ontario L4C 9M7, Canada
    Recruiting
  • Novartis Investigative Site
    Toronto, Ontario M4E 1R7, Canada
    Recruiting
  • Novartis Investigative Site
    Saint-Jérôme, Quebec J7Z 7E2, Canada
    Recruiting
  • Novartis Investigative Site
    Sherbrooke, Quebec J1L 0H8, Canada
    Recruiting
  • Novartis Investigative Site
    Saskatoon, Saskatchewan S7N0N5, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Feb 2028, 25 months after the start.

Of 46 observational studies under Hidradenitis Suppurativa, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 25. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 15, 2025
StartActual
Dec 12, 2025
Primary completionEst.
Feb 11, 2028
CompletionEst.
Feb 11, 2028
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07282015
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Dec 12, 2025
Primary completion
Feb 11, 2028 (estimated)
Completion
Feb 11, 2028 (estimated)
Last update
Jun 23, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion